114 related articles for article (PubMed ID: 11716232)
21. Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma.
Wang TS; Ocal IT; Sosa JA; Cox H; Roman S
Thyroid; 2008 Aug; 18(8):889-94. PubMed ID: 18651827
[TBL] [Abstract][Full Text] [Related]
22. Procalcitonin can be used for monitoring sepsis in patients with medullary thyroid carcinoma.
Novotny AR; Luppa P; Rosenberg R; Schneider H; Maak M; Bartels H; Holzmann B; Friess H
Thyroid; 2009 Nov; 19(11):1287-9. PubMed ID: 19785521
[No Abstract] [Full Text] [Related]
23. Biochemical results of reoperations for medullary thyroid carcinoma.
Fernandez Vila JM; Peix JL; Mandry AC; Mezzadri NA; Lifante JC
Laryngoscope; 2007 May; 117(5):886-9. PubMed ID: 17473689
[TBL] [Abstract][Full Text] [Related]
24. [The routine immunohistochemical diagnosis and surgical treatment of medullary carcinoma of the thyroid].
Gavrailov M; Petkov R; Mladenov B; Todorov G; Kŭtev N
Khirurgiia (Sofiia); 1995; 48(2):17-9. PubMed ID: 8531439
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
[TBL] [Abstract][Full Text] [Related]
26. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
[TBL] [Abstract][Full Text] [Related]
27. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level.
Machens A; Schneyer U; Holzhausen HJ; Dralle H
J Clin Endocrinol Metab; 2005 Apr; 90(4):2029-34. PubMed ID: 15634717
[TBL] [Abstract][Full Text] [Related]
28. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
[TBL] [Abstract][Full Text] [Related]
29. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature.
Dora JM; Canalli MH; Capp C; Puñales MK; Vieira JG; Maia AL
Thyroid; 2008 Aug; 18(8):895-9. PubMed ID: 18651801
[TBL] [Abstract][Full Text] [Related]
30. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
Mirallié E; Iacobone M; Sebag F; Henry JF
Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
[TBL] [Abstract][Full Text] [Related]
31. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
[TBL] [Abstract][Full Text] [Related]
32. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?
Machens A; Hauptmann S; Dralle H
J Clin Endocrinol Metab; 2008 Jun; 93(6):2234-8. PubMed ID: 18364379
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of "prophylactic therapy" for familial medullary thyroid cancer.
Schellhaas E; König C; Frank-Raue K; Buhr HJ; Hotz HG
Surgery; 2009 Nov; 146(5):906-12. PubMed ID: 19744457
[TBL] [Abstract][Full Text] [Related]
34. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
[TBL] [Abstract][Full Text] [Related]
35. Sporadic hypercalcitoninemia: clinical and therapeutic consequences.
Scheuba C; Kaserer K; Moritz A; Drosten R; Vierhapper H; Bieglmayer C; Haas OA; Niederle B
Endocr Relat Cancer; 2009 Mar; 16(1):243-53. PubMed ID: 18987170
[TBL] [Abstract][Full Text] [Related]
36. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
Bockhorn M; Frilling A; Rewerk S; Liedke M; Dirsch O; Schmid KW; Broelsch CE
Thyroid; 2004 Jun; 14(6):468-70. PubMed ID: 15242577
[TBL] [Abstract][Full Text] [Related]
37. Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma.
Learoyd DL; Roach PJ; Briggs GM; Delbridge LW; Wilmshurst EG; Robinson BG
J Nucl Med; 1997 Feb; 38(2):227-30. PubMed ID: 9025742
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity of circulating calcitonin levels: relations with calcitonin biosynthesis in medullary thyroid carcinomas.
Guliana JM; Taboulet J; Calmettes C; Milhaud G; Moukhtar MS; Jullienne A
Nucl Med Biol; 1994 Apr; 21(3):359-68. PubMed ID: 9234301
[TBL] [Abstract][Full Text] [Related]
39. Radioactive iodine treatment in medullary thyroid carcinoma.
Faik Erdogan M; Gursoy A; Erdogan G; Kamel N
Nucl Med Commun; 2006 Apr; 27(4):359-62. PubMed ID: 16531922
[TBL] [Abstract][Full Text] [Related]
40. Review analysis of medullary carcinoma of the thyroid: a 15-year Indian experience.
Dorairajan N; Siddharth D; Kanna S
Int Surg; 2006; 91(3):162-7. PubMed ID: 16845858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
